IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 67.01

Change

+0.86 (+1.30)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.96% 29% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.96% 29% F 46% F
Trailing 12 Months  
Capital Gain 5.71% 62% D 47% F
Dividend Return 1.46% 94% A 23% F
Total Return 7.17% 67% D+ 40% F
Trailing 5 Years  
Capital Gain 22.75% 48% F 61% D-
Dividend Return 8.67% 95% A 26% F
Total Return 31.42% 62% D 56% F
Average Annual (5 Year Horizon)  
Capital Gain 4.27% 48% F 48% F
Dividend Return 5.65% 57% F 45% F
Total Return 1.38% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.38% 71% C- 66% D+
Risk Adjusted Return 36.73% 67% D+ 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike